Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones?

Current Diabetes Reviews

Volumn 5, Issue 3, 2009, Pages 201-209

  Lawless, M W ^a   O'Byrne, K J ^b   Gray, S G ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; AMINO ACID ACETYLTRANSFERASE; BUTYRIC ACID; CHAPERONE; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 94; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INSULIN; LEPTIN; LYSINE ACETYLTRANSFERASE; RESVERATROL; ROMIDEPSIN; SIRTUIN 1; THEOPHYLLINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; 4-PHENYLBUTYRIC ACID; ACYLTRANSFERASE; ANTIDIABETIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; ENZYME INHIBITOR; KINAMYCIN ACETYLTRANSFERASE I;

ANEMIA; CATARACT; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; CYSTIC FIBROSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG DOSE ESCALATION; ECG ABNORMALITY; EMPHYSEMA; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; FATIGUE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE TARGETING; GLAUCOMA; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPOGLYCEMIA; KIDNEY CANCER; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESPIRATORY DISTRESS; RETINITIS; REVIEW; SIDE EFFECT; SOLID TUMOR; SUDDEN DEATH; T CELL LYMPHOMA; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; ENZYMOLOGY; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ACETYLTRANSFERASES; CHROMATIN ASSEMBLY AND DISASSEMBLY; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; ENDOPLASMIC RETICULUM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR CHAPERONES; OBESITY; PHENYLBUTYRATES;

EID: 70349785791     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909788920956     Document Type: Review

References (163)

1. IDF. Diabetes Atlas. Third ed. International Diabetes Federation; 2006.
2. Gray SG, De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabet Metab Res Rev 2005; 21: 416-433 (Pubitemid 41320653)
3. Batta K, Das C, Gadad S, Shandilya J, Kundu TK. Reversible acetylation of non histone proteins: role in cellular function and disease. Subcell Biochem 2007; 41: 193-212.
4. Lee J, Saha PK, Yang QH, et al. Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. Proc Natl Acad Sci USA 2008; 105: 19229-19234
5. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008; 205: 2409-2417
6. Li Y, Reddy MA, Miao F, et al. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 2008; 283: 26771-26781
7. Park YJ, Luger K. Histone chaperones in nucleosome eviction and histone exchange. Curr Opin Struct Biol 2008; 18: 282-289
8. Meimaridou E, Gooljar SB, Chapple JP. From hatching to dispatching: the multiple cellular roles of the Hsp70 molecular chaperone machinery. J Mol Endocrinol 2009; 42: 1-9.
9. Barginear MF, Van Poznak C, Rosen N, Modi S, Hudis CA, Budman DR. The heat shock protein 90 chaperone complex: an evolving therapeutic target. Curr Cancer Drug Targets 2008; 8: 522-532
10. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008; 283(27): 18473-18477
11. Hebert DN, Molinari M. In and out of the ER: protein folding, quality control, degradation, and related human diseases. Physiol Rev 2007; 87: 1377-1408 (Pubitemid 350041473)
12. Rapoport TA. Protein translocation across the eukaryotic endoplasmic reticulum and bacterial plasma membranes. Nature 2007; 450: 663-669
13. Quinones QJ, de Ridder GG, Pizzo SV. GRP78: a chaperone with diverse roles beyond the endoplasmic reticulum. Histol Histopathol 2008; 23: 1409-1416
14. Paris S, Denis H, Delaive E, et al. Up-regulation of 94-kDa glucose-regulated protein by hypoxia-inducible factor-1 in human endothelial cells in response to hypoxia. FEBS Lett 2005; 579: 105-114 (Pubitemid 40023381)
15. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008; 29: 42-61. (Pubitemid 351252746)
16. Scheuner D, Kaufman RJ. The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes. Endocr Rev 2008; 29: 317-333 (Pubitemid 351679702)
17. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57: 3169-3176
18. Rutkowski DT, Kaufman RJ. A trip to the ER: coping with stress. Trends Cell Biol 2004; 14: 20-28
19. Lai E, Teodoro T, Volchuk A. Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda) 2007; 22: 193-201.
20. Caruso ME, Chevet E. Systems biology of the endoplasmic reticulum stress response. Subcell Biochem 2007; 43: 277-298
21. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008; 9: 944-957
22. Kim I, Xu W, Reed JC. Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013-1030
23. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-529 (Pubitemid 46985379)
24. Pahl HL, Baeuerle PA. The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 1997; 22: 63-67
25. Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005; 115: 2656-2664 (Pubitemid 41434389)
26. Heath-Engel HM, Chang NC, Shore GC. The endoplasmic reticulum in apoptosis and autophagy: role of the BCL-2 protein family. Oncogene 2008; 27: 6419-6433
27. Støy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 2007; 104: 15040-15044 (Pubitemid 47619589)
28. Colombo C, Porzio O, Liu M, et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest 2008; 118: 2148-2156 (Pubitemid 351872333)
29. Johnson CA, White DA, Lavender JS, O'Neill LP, Turner BM. Human Class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and Co-immunoprecipitate with the ATP-dependent Chaperone Protein Hsp70. J Biol Chem 2002; 277: 9590-9597
30. Park YJ, Sudhoff KB, Andrews AJ, Stargell LA, Luger K. Histone chaperone specificity in Rtt109 activation. Nat Struct Mol Biol 2008; 15: 957-964
31. Berndsen CE, Tsubota T, Lindner SE, et al. Molecular functions of the histone acetyltransferase chaperone complex Rtt109-Vps75. Nat Struct Mol Biol 2008; 15: 948-956
32. Kaplan T, Liu CL, Erkmann JA, et al. Cell cycle- and chaperone-mediated regulation of H3K56ac incorporation in yeast. PLoS Genet 2008; 4: 1-16.
33. Hiraga S, Botsios S, Donaldson AD. Histone H3 lysine 56 acetylation by Rtt109 is crucial for chromosome positioning. J Cell Biol 2008; 183: 641-651
34. Tang Y, Meeth K, Jiang E, Luo C, Marmorstein R. Structure of Vps75 and implications for histone chaperone function. Proc Natl Acad Sci USA 2008; 105: 12206-12211
35. Chen CC, Carson JJ, Feser J, et al. Acetylated lysine 56 on histone H3 drives chromatin assembly after repair and signals for the completion of repair. Cell 2008; 134: 231-243 (Pubitemid 352010334)
36. Li Q, Zhou H, Wurtele H, et al. Acetylation of histone H3 lysine 56 regulates replication-coupled nucleosome assembly. Cell 2008; 134: 244-255 (Pubitemid 352010333)
37. Williams SK, Truong D, Tyler JK. Acetylation in the globular core of histone H3 on lysine-56 promotes chromatin disassembly during transcriptional activation. Proc Natl Acad Sci USA 2008; 105: 9000-9005
38. Miller A, Yang B, Foster T, Kirchmaier AL. Proliferating cell nuclear antigen and ASF1 modulate silent chromatin in Saccharomyces cerevisiae via lysine 56 on histone H3. Genetics 2008; 179: 793-809.
39. Fillingham J, Recht J, Silva AC, et al. Chaperone control of the activity and specificity of the histone H3 acetyltransferase Rtt109. Mol Cell Biol 2008; 28: 4342-4353 (Pubitemid 351904956)
40. LeRoy G, Rickards B, Flint SJ. The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 2008; 30: 51-60.
41. Munemasa Y, Suzuki T, Aizawa K, et al. Promoter region-specific histone incorporation by the novel histone chaperone ANP32B and DNA-binding factor KLF5. Mol Cell Biol 2008; 28: 1171-1181 (Pubitemid 351160072)
42. Han J, Zhou H, Li Z, Xu RM, Zhang Z. Acetylation of lysine 56 of histone H3 catalyzed by RTT109 and regulated by ASF1 is required for replisome integrity. J Biol Chem 2007; 282: 28587-28596 (Pubitemid 47606001)
43. Rufiange A, Jacques PE, Bhat W, Robert F, Nourani A. Genome-wide replication-independent histone H3 exchange occurs predominantly at promoters and implicates H3 K56 acetylation and Asf1. Mol Cell 2007; 27: 393-405. (Pubitemid 47135636)
44. Schneider J, Bajwa P, Johnson FC, Bhaumik SR, Shilatifard A. Rtt109 is required for proper H3K56 acetylation: a chromatin mark associated with the elongating RNA polymerase II. J Biol Chem 2006; 281: 37270-37274 (Pubitemid 46042030)
45. Adkins MW, Carson JJ, English CM, Ramey CJ, Tyler JK. The histone chaperone anti-silencing function 1 stimulates the acetylation of newly synthesized histone H3 in S-phase. J Biol Chem 2007; 282: 1334-1340
46. Recht J, Tsubota T, Tanny JC, et al. Histone chaperone Asf1 is required for histone H3 lysine 56 acetylation, a modification associated with S phase in mitosis and meiosis. Proc Natl Acad Sci USA 2006; 103: 6988-6993
47. Barman HK, Takami Y, Nishijima H, Shibahara K, Sanematsu F, Nakayama T. Histone acetyltransferase-1 regulates integrity of cytosolic histone H3-H4 containing complex. Biochem Biophys Res Commun 2008; 373: 624-630
48. Jin C, Kato K, Chimura T, et al. Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nat Struct Mol Biol 2006; 13: 331-338 (Pubitemid 43873504)
49. Swaminathan V, Kishore AH, Febitha KK, Kundu TK. Human histone chaperone nucleophosmin enhances acetylation-dependent chromatin transcription. Mol Cell Biol 2005; 25: 7534-7545 (Pubitemid 41170116)
50. Thomas M, Dadgar N, Aphale A, et al. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J Biol Chem 2004; 279: 8389-8395 (Pubitemid 38294731)
51. Kekatpure VD, Dannenberg AJ, Subbaramaiah K. HDAC6 modulates HSP90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem 2009; 284: 7436-7445
52. Suuronen T, Ojala J, Hyttinen JM, et al. Regulation of ER alpha signaling pathway in neuronal HN10 cells: role of protein acetylation and Hsp90. Neurochem Res 2008; 33: 1768-1775
53. Fiskus W, Ren Y, Mohapatra A, et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007; 13: 4882-4890 (Pubitemid 47294796)
54. Kovacs JJ, Murphy PJ, Gaillard S, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607 (Pubitemid 40726236)
55. Giustiniani J, Daire V, Cantaloube I, et al. Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53. Cell Signal 2009; 21: 529-539
56. Bardag-Gorce F, Dedes J, French BA, Oliva JV, Li J, French SW. Mallory body formation is associated with epigenetic phenotypic change in hepatocytes in vivo. Exp Mol Pathol 2007; 83: 160-168 (Pubitemid 47320655)
57. Hanada S, Harada M, Kumemura H, et al. Oxidative stress induces the endoplasmic reticulum stress and facilitates inclusion formation in cultured cells. J Hepatol 2007; 47: 93-102. (Pubitemid 46830718)
58. Ohoka N, Hattori T, Kitagawa M, Onozaki K, Hayashi H. Critical and functional regulation of CHOP (C/EBP Homologous Protein) through the N-terminal portion. J Biol Chem 2007; 282: 35687-35694 (Pubitemid 350277151)
59. Baumeister P, Luo S, Skarnes WC, et al. Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell Biol 2005; 25: 4529-4540 (Pubitemid 40705758)
60. Donati G, Imbriano C, Mantovani R. Dynamic recruitment of transcription factors and epigenetic changes on the ER stress response gene promoters. Nucleic Acids Res 2006; 34: 3116-3127 (Pubitemid 44540437)
61. Doody GM, Stephenson S, Tooze RM. BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. Eur J Immunol 2006; 36: 1572-1582 (Pubitemid 43942145)
62. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol 2000; 20: 2592-2603 (Pubitemid 30152065)
63. Zeng L, Lu M, Mori K, et al. ATF6 modulates SREBP2-mediated lipogenesis. EMBO J 2004; 23: 950-958
64. Nozaki J, Kubota H, Yoshida H, et al. The endoplasmic reticulum stress response is stimulated through the continuous activation of transcription factors ATF6 and XBP1 in Ins2+/Akita pancreatic beta cells. Genes Cells 2004; 9: 261-270 (Pubitemid 38380233)
65. Sugden MC, Holness MJ. Role of nuclear receptors in the modulation of insulin secretion in lipid-induced insulin resistance. Biochem Soc Trans 2008; 36: 891-900.
66. Pratt WB, Morishima Y, Murphy M, Harrell M. Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol 2006; 172: 111-138
67. Murphy PJ, Morishima Y, Kovacs JJ, Yao TP, Pratt WB. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/ deacetylation of the chaperone. J Biol Chem 2005; 280: 33792-33799 (Pubitemid 41443098)
68. Kelly A, Bowen H, Jee YK, et al. The glucocorticoid receptor beta isoform can mediate transcriptional repression by recruiting histone deacetylases. J Allergy Clin Immunol 2008; 121: 203-208
69. Amat R, Solanes G, Giralt M, Villarroya F. SIRT1 is involved in glucocorticoid-mediated control of uncoupling protein-3 gene transcription. J Biol Chem 2007; 282: 34066-34076 (Pubitemid 350159429)
70. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20: 6891-6903 (Pubitemid 30700806)
71. Wiper-Bergeron N, Salem HA, Tomlinson JJ, Wu D, Hache RJ. Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation of C/EBPbeta by GCN5. Proc Natl Acad Sci USA 2007; 104: 2703-2708 (Pubitemid 46327943)
72. Wiper-Bergeron N, Wu D, Pope L, Schild-Poulter C, Hache RJ. Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J 2003; 22: 2135-2145 (Pubitemid 36569220)
73. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 2000; 278: C259-67.
74. Burrows JA, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000; 97: 1796-1801
75. Qi X, Hosoi T, Okuma Y, Kaneko M, Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol Pharmacol 2004; 66: 899-908. (Pubitemid 39319462)
76. Vilatoba M, Eckstein C, Bilbao G, et al. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery 2005; 138: 342-351 (Pubitemid 41253820)
77. Kubota K, Niinuma Y, Kaneko M, et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J Neurochem 2006; 97: 1259-1268 (Pubitemid 43725566)
78. Liu XL, Done SC, Yan K, Kilpelainen P, Pikkarainen T, Tryggvason K. Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J Am Soc Nephrol 2004; 15: 1731-1738 (Pubitemid 38822051)
79. Yam GH, Roth J, Zuber C. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality. Biochem Biophys Res Commun 2007; 360: 375-380 (Pubitemid 47030355)
80. Datta R, Waheed A, Shah GN, Sly WS. Signal sequence mutation in autosomal dominant form of hypoparathyroidism induces apoptosis that is corrected by a chemical chaperone. Proc Natl Acad Sci USA 2007; 104: 19989-19994
81. Watanabe N, Lam E. BAX inhibitor-1 modulates endoplasmic reticulum stress-mediated programmed cell death in Arabidopsis. J Biol Chem 2008; 283: 3200-3210
82. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6: 119-126 (Pubitemid 36124279)
83. Singh OV, Vij N, Mogayzel PJ, Jr., Jozwik C, Pollard HB, Zeitlin PL. Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 cystic fibrosis bronchial epithelial cells. J Proteome Res 2006; 5: 562-571 (Pubitemid 43364096)
84. Vij N, Fang S, Zeitlin PL. Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: therapeutic implications. J Biol Chem 2006; 281: 17369-17378 (Pubitemid 43909545)
85. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-490
86. Rubenstein RC, Lyons BM. Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am J Physiol Lung Cell Mol Physiol 2001; 281: L43-51.
87. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100: 2457-2465
88. Lim M, McKenzie K, Floyd AD, Kwon E, Zeitlin PL. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol 2004; 31: 351-357 (Pubitemid 39180306)
89. Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet 2006; 15: 3012-3023 (Pubitemid 44530705)
90. Choo-Kang LR, Zeitlin PL. Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 2001; 281: L58-68.
91. Cheong N, Madesh M, Gonzales LW, et al. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem 2006; 281: 9791-9800 (Pubitemid 43864698)
92. Mulhern ML, Madson CJ, Kador PF, Randazzo J, Shinohara T. Cellular osmolytes reduce lens epithelial cell death and alleviate cataract formation in galactosemic rats. Mol Vis 2007; 13: 1397-1405
93. Yam GH, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. Invest Ophthalmol Vis Sci 2007; 48: 1683-90.
94. Bonapace G, Waheed A, Shah GN, Sly WS. Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17. Proc Natl Acad Sci USA 2004; 101: 12300-12305
95. Hayashi H, Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 2007; 45: 1506-1516 (Pubitemid 46918335)
96. de Almeida SF, Picarote G, Fleming JV, Carmo-Fonseca M, Azevedo JE, de Sousa M. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J Biol Chem 2007; 282: 27905-27912 (Pubitemid 47529490)
97. Tveten K, Holla OL, Ranheim T, Berge KE, Leren TP, Kulseth MA. 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. FEBS J 2007; 274: 1881-1893 (Pubitemid 46587991)
98. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118(9): 2992-3002.
99. Coll AP, Farooqi IS, O'Rahilly S. The hormonal control of food intake. Cell 2007; 129: 251-262
100. Hosoi T, Sasaki M, Miyahara T, et al. Endoplasmic reticulum stress induces leptin resistance. Mol Pharmacol 2008; 74: 1610-1619
101. Ozcan L, Ergin AS, Lu A, et al. Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab 2009; 9: 35-51.
102. Ozcan U, Yilmaz E, Ozcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 2006; 313: 1137-1140 (Pubitemid 44300242)
103. Wang JF, Bown C, Young LT. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol 1999; 55: 521-527 (Pubitemid 29128109)
104. Shi Y, Gerritsma D, Bowes AJ, Capretta A, Werstuck GH. Induction of GRP78 by valproic acid is dependent upon histone deacetylase inhibition. Bioorg Med Chem Lett 2007; 17: 4491-4494 (Pubitemid 47058957)
105. Bown CD, Wang JF, Young LT. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 2000; 39: 2162-2169 (Pubitemid 30645639)
106. Chen B, Wang JF, Young LT. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol Psychiatry 2000; 48: 658-664 (Pubitemid 30734234)
107. Shao L, Sun X, Xu L, Young LT, Wang JF. Mood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci 2006; 78: 1317-1323 (Pubitemid 43199952)
108. Corson TW, Woo KK, Li PP, Warsh JJ. Cell-type specific regulation of calreticulin and Bcl-2 expression by mood stabilizer drugs. Eur Neuropsychopharmacol 2004; 14: 143-150
109. Wang JF, Bown CD, Chen B, Young LT. Identification of mood stabilizer-regulated genes by differential-display PCR. Int J Neuropsychopharmacol 2001; 4: 65-74. (Pubitemid 32390636)
110. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321: 892-901. (Pubitemid 46762687)
111. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89: 1358-1367 (Pubitemid 38802657)
112. Morland C, Boldingh KA, Iversen EG, Hassel B. Valproate is neuroprotective against malonate toxicity in rat striatum: an association with augmentation of high-affinity glutamate uptake. J Cereb Blood Flow Metab 2004; 24: 1226-1234 (Pubitemid 39482484)
113. Inden M, Kitamura Y, Takeuchi H, et al. Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone. J Neurochem 2007; 101: 1491-1504 (Pubitemid 46848844)
114. Pan T, Li X, Xie W, Jankovic J, Le W. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS Lett 2005; 579: 6716-6720
115. Hiroi T, Wei H, Hough C, Leeds P, Chuang DM. Protracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J 2005; 5: 102-111 (Pubitemid 40468117)
116. Wang JF, Azzam JE, Young LT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003; 116: 485-489
117. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005; 58: 879-884 (Pubitemid 41790716)
118. Cui J, Shao L, Young LT, Wang JF. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007; 144: 1447-1453 (Pubitemid 46123817)
119. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003; 115: 727-738
120. Boyault C, Gilquin B, Zhang Y, et al. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J 2006; 25: 3357-3366 (Pubitemid 44141793)
121. Boyault C, Zhang Y, Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007; 21: 2172-2181 (Pubitemid 47360839)
122. Gao YS, Hubbert CC, Lu J, Lee YS, Lee JY, Yao TP. Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol 2007; 27: 8637-8647
123. Wang Y, Wang SY, Zhang XH, et al. FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Biophys Res Commun 2007; 356: 998-1003.
124. Scroggins BT, Robzyk K, Wang D, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 2007; 25: 151-159 (Pubitemid 46049066)
125. Edwards A, Li J, Atadja P, Bhalla K, Haura EB. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 2007; 6: 2515-2524 (Pubitemid 47480417)
126. Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-26734 (Pubitemid 41040705)
127. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 2006; 26: 2019-2028 (Pubitemid 43346906)
128. Matthias P, Yoshida M, Khochbin S. HDAC6 a new cellular stress surveillance factor. Cell Cycle 2008; 7: 7-10.
129. Chung J, Nguyen AK, Henstridge DC, et al. HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 2008; 105: 1739-1744 (Pubitemid 351346584)
130. Cecconi D, Donadelli M, Rinalducci S, et al. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. Proteomics 2007; 7: 1644-1653 (Pubitemid 46841825)
131. Zhao YM, Chen X, Sun H, et al. Effects of histone deacetylase inhibitors on transcriptional regulation of the hsp70 gene in Drosophila. Cell Res 2006; 16: 566-576 (Pubitemid 43920285)
132. Ovakim DH, Heikkila JJ. Effect of histone deacetylase inhibitors on heat shock protein gene expression during Xenopus development. Genesis 2003; 36: 88-96. (Pubitemid 36818668)
133. Chen T, Sun H, Lu J, et al. Histone acetylation is involved in hsp70 gene transcription regulation in Drosophila melanogaster. Arch Biochem Biophys 2002; 408: 171-176 (Pubitemid 36027036)
134. Vanhooren V, Liu XE, Desmyter L, et al. Over-Expression of Heat Shock Protein 70 in Mice Is Associated with Growth Retardation, Tumor Formation, and Early Death. Rejuvenation Res 2008; 11(6): 1013-1020
135. Montgomery RL, Potthoff MJ, Haberland M, et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008; 118: 3588-3597
136. Marshall JL, Rizvi N, Kauh J, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002; 2: 325-332 (Pubitemid 35265981)
137. Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8: 718-728 (Pubitemid 34742100)
138. Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 2005; 105: 959-967 (Pubitemid 40170861)
139. Fouladi M, Furman WL, Chin T, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol 2006; 24: 3678-3685 (Pubitemid 46630544)
140. Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer 2006; 5: 57-60.
141. Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006; 123: 762-773
142. Shah MH, Binkley P, Chan K, et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2006; 12: 3997-4003. (Pubitemid 44078086)
143. Ghosh HS. The anti-aging, metabolism potential of SIRT1. Curr Opin Investig Drugs 2008; 9: 1095-1102
144. Kwon HS, Ott M. The ups and downs of SIRT1. Trends Biochem Sci 2008; 33: 517-525
145. Sun C, Zhang F, Ge X, et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007; 6: 307-319 (Pubitemid 47468091)
146. Boily G, Seifert EL, Bevilacqua L, et al. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS ONE 2008; 3: 1-12.
147. Gerhart-Hines Z, Rodgers JT, Bare O, et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J 2007; 26: 1913-1923 (Pubitemid 46624046)
148. Zhang J. The direct involvement of SirT1 in insulin-induced insulin receptor substrate-2 tyrosine phosphorylation. J Biol Chem 2007; 282: 34356-34364 (Pubitemid 350159485)
149. Lee JH, Song MY, Song EK, et al. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes 2009; 58: 344-351
150. Banks AS, Kon N, Knight C, et al. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 2008; 8: 333-341
151. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci 2003; 60: 1990-1997 (Pubitemid 37222594)
152. Sequeira J, Boily G, Bazinet S, et al. sirt1-null mice develop an autoimmune-like condition. Exp Cell Res 2008; 314: 3069-3074
153. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 2008; 42: 397-404.
154. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-716 (Pubitemid 350207685)
155. Nayagam VM, Wang X, Tan YC, et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J Biomol Screen 2006; 11: 959-967 (Pubitemid 44847150)
156. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005; 46: 1369-1379 (Pubitemid 43109800)
157. Qiang L, Wang H, Farmer SR. Adiponectin Secretion Is Regulated by SIRT1 and the endoplasmic reticulum oxidoreductase Ero1-L{alpha}. Mol Cell Biol 2007; 27: 4698-4707
158. Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 2006; 147: 865-874 (Pubitemid 43113004)
159. Heller SR. Minimizing hypoglycemia while maintaining glycemic control in diabetes. Diabetes 2008; 57: 3177-3183
160. Joost HG, Steinfelder HJ. Effects of theophylline on insulin receptors and insulin action in the adipocyte. Mol Cell Biochem 1983; 57: 177-183 (Pubitemid 14205119)
161. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695 (Pubitemid 39258317)
162. Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921-8926 (Pubitemid 34693659)
163. Lawless MW, Norris S, O'Byrne KJ, Gray SG. Targeting Histone Deacetylases for the treatment of disease. J Cell Mol Med 2008 Nov 3. [Epub ahead of print]